Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

Amgen Contributes $2 Million to Groundbreaking Program Providing Cancer Patients of all Backgrounds Access to U.S. Clinical Trials THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participa...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news